Increased levels of TIMP-4 in BRCA tumors have been associated with tumor progression of ductal carcinoma in situ, and a shorter disease-free survival in BRCA patients, especially in estrogen receptor (ER)-negative tumors [40]. This evidence concerns the gene ESR1 and invasive breast carcinoma.